Why Omeros Corporation’s (OMER) Stock Is Up 12.56%
As of Monday, July 27, Omeros Corporation’s OMER share price has surged by 12.56%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Commentary & Analysis
Why Omeros Corporation’s (OMER) Stock Is Up 14.30%
As of Monday, July 27, Omeros Corporation’s OMER share price has surged by 14.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Omeros Corporation’s (OMER) Stock Is Up 6.24%
As of Friday, July 17, Omeros Corporation’s OMER share price has surged by 6.24%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Omeros Corporation’s (OMER) Stock Is Down 10.17%
As of Thursday, July 16, Omeros Corporation’s OMER share price has dipped by 10.17%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Omeros Corporation’s (OMER) Stock Is Down 6.94%
As of Thursday, July 16, Omeros Corporation’s OMER share price has dipped by 6.94%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | OMER | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $856.9 | $579.1 | 44% |
|
| Shares Out (Mil) | 90.1 | 43.0 | 60% |
|
| Institutional Ownership | 92.5% | 84.3% | 62% |
|
| Float (Mil) | 69.8 | 46.8 | 55% |
|
| Beta | 2.66 | 0.62 | 97% |
|
| Avg Daily Volume (000s) | 1,554 | 285 | 78% |
|
| Price Change (52-week) |
207.5% | 63.8% | 97% |
|
| Growth | OMER | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 52.3% | (1.4%) | 94% |
|
| EPS (5yr) | 53.4% | 14.9% | 94 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (5.1%) | (14.9%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.330) | ($0.205) | $0.380 | |
| Month Ago EPS | $0.265 | $0.380 | ($0.155) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.235) | ($0.525) | $1.287 | |
| Year/Year Chg | (157.9%) | 169.7% | (1,988%) | |
| Financials | OMER | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $272 | 9% |
|
| Net Income (TTM) (Mil) | $86 | ($11) | 60% |
|
| EPS (TTM) | $1.287 | ($0.500) | 64% |
|
| Operating Cash Flow (TTM) (Mil) | ($95) | ($6) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $4 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $200 | $7 | 50% |
|
| Enterprise Value (Q1) (Mil) | $1,052 | $522 | 42% |
|
| Valuation | OMER | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | 10.0 | 20.5 | 16% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.2 | 8% |
|
| Ratios | OMER | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (190.5%) | 65.9% | 1% |
|
| Net Margin | 871.0% | 0.7% | 100% |
|
| ROA | 33.1% | (24.6%) | 99% |
|
| ROE | (62.2%) | (19.7%) | 13% |
|
| Liabilities to Assets | 122.1% | 35.5% | 97% |
|
| F-Score | 3 | 3 | 19% |
|
Omeros Corporation did not pass any screens on 7/31/2026.
